TCGA-BH-A201-01A-11R-A14M-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 29
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.590
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- TGF_BETA_SIGNALING+0.530
- UV_RESPONSE_DN+0.500
- ANDROGEN_RESPONSE+0.460
- TNFA_SIGNALING_VIA_NFKB+0.430
- CHOLESTEROL_HOMEOSTASIS+0.340
- ESTROGEN_RESPONSE_EARLY+0.330
- COAGULATION+0.280
- UNFOLDED_PROTEIN_RESPONSE+0.250
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.410
- ALLOGRAFT_REJECTION-0.300
- INTERFERON_ALPHA_RESPONSE-0.280
- DNA_REPAIR-0.210
- FATTY_ACID_METABOLISM-0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.190
- INTERFERON_GAMMA_RESPONSE-0.170
- E2F_TARGETS-0.150
- ADIPOGENESIS-0.110
- PEROXISOME-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A1PG-01A-11R-A144-07 | — | A | 0.868 |
| 2 | 20030016.LumA | — | B | 0.852 |
| 3 | TCGA-73-4668-01A-01R-1206-07 | — | cohortA1 | 0.834 |
| 4 | 299613f5-2f9a-4687-ab0c-323bf38f3699 | — | — | 0.828 |
| 5 | TCGA-77-8130-01A-11R-2247-07 | — | cohortSQ1 | 0.820 |
| 6 | TCGA-85-A50M-01A-21R-A262-07 | — | cohortSQ1 | 0.811 |
| 7 | TCGA-34-5928-01A-11R-1820-07 | — | cohortSQ1 | 0.803 |
| 8 | SRR8943050 | — | — | 0.802 |
| 9 | MNG119 | — | — | 0.786 |
| 10 | TCGA-A1-A0SM-01A-11R-A084-07 | — | C | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.590 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.530 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.500 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.460 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |